**Malignancies such as:**
- Thyroid cancer
- Melanoma
- Lymphoproliferative disorders and lymphoma

**LEMTRADA treatment can increase the risk of:**

**Autoimmune conditions such as:**
- A bleeding problem called immune thrombocytopenia (ITP)
- Other blood disorders (including neutropenia, hemolytic anemia, and pancytopenia)
- Disorders of the thyroid gland (hypo/hyperthyroidism)
- Kidney disorders (nephropathies, including anti-glomerular basement membrane (anti-GBM) disease)
- Liver disorders (autoimmune hepatitis)

**Infusion reactions (may occur more than 24 hours after the infusion), such as:**
- Hypersensitivity reactions (including anaphylaxis)
- Fever
- Hives
- Irregular heartbeat
- Nausea
- Chest pain
- Low blood pressure

**Strokes and tears in the arteries that provide blood to the brain. Symptoms of stroke or tear in the arteries include:**
- Drooping of parts of your face
- Weakness on one side
- Sudden severe headache
- Difficulty with speech
- Neck pain

**Infusion reactions (may occur more than 24 hours after the infusion), such as:**
- Hypersensitivity reactions (including anaphylaxis)
- Fever
- Hives
- Irregular heartbeat
- Nausea
- Chest pain
- Low blood pressure

**Infusion reactions (may occur more than 24 hours after the infusion), such as:**
- Hypersensitivity reactions (including anaphylaxis)
- Fever
- Hives
- Irregular heartbeat
- Nausea
- Chest pain
- Low blood pressure

**LEMTRADA has been treated with LEMTRADA, a treatment for multiple sclerosis (MS), which lowers the number of circulating white blood cells for a period of time after treatment and also affects the immune system. Therefore, the patient is part of a laboratory monitoring program that continues until 4 years after his/her last treatment.**

**For more information on LEMTRADA, including important risks, please refer to the Prescribing Information and/or www.LEMTRADAREMS.com.**

**For information on LEMTRADA or the LEMTRADA REMS, call 1-855-676-6326.**

©2022 Genzyme Corporation. All rights reserved.